Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.0M | $162M | $451M | $788M | $1.05B | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Revenue growth | — | 977.5% | 179.2% | 74.7% | 32.7% | 8.4% | 31.3% | 26.8% | 24.8% | 21.4% |
| Operating income | -$147M | -$131M | $36.8M | $72.3M | $163M | $103M | $249M | $251M | $571M | $619M |
| Operating margin | -982.5% | -81.3% | 8.2% | 9.2% | 15.6% | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% |
| Net income | -$141M | -$143M | $21.1M | $37.0M | $407M | $89.6M | $155M | $250M | $341M | $479M |
| Net margin | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% |
| EPS (diluted) | -$1.63 | -$1.62 | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$106M | -$94.3M | $101M | $147M | $229M | $257M | $339M | $390M | $595M | $783M |
| Capital expenditures | $4.11M | $6.94M | $24.8M | $14.7M | $10.9M | $23.4M | $16.5M | $28.3M | $38.2M | $34.0M |
| Free cash flow | -$110M | -$101M | $76.6M | $132M | $218M | $233M | $323M | $362M | $557M | $749M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $0.00 | $300M | $168M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $83.3M | $255M | $142M | $112M | $187M | $341M | $263M | $251M | $233M | $713M |
| Total assets | $365M | $818M | $993M | $1.31B | $1.73B | $2.07B | $2.37B | $3.25B | $3.72B | $4.63B |
| Total liabilities | $50.2M | $445M | $512M | $669M | $609M | $699M | $661M | $1.02B | $1.13B | $1.38B |
| Shareholders' equity | $315M | $372M | $481M | $637M | $1.13B | $1.37B | $1.71B | $2.23B | $2.59B | $3.25B |
| Retained earnings | -$1.06B | -$1.20B | -$1.18B | -$1.13B | -$725M | -$636M | -$407M | -$157M | $29.2M | $448M |
| Shares (wtd avg diluted) | 86.7M | 88.1M | 95.4M | 95.7M | 97.8M | 97.9M | 98.9M | 101M | 104M | 103M |
Every figure is extracted from NEUROCRINE BIOSCIENCES INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.